Theracryf (TCF)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

0.24p
   
  • Change Today:
      0.010p
  • 52 Week High: 1.22
  • 52 Week Low: 0.20
  • Currency: UK Pounds
  • Shares Issued: 2,148.96m
  • Volume: 5,147,033
  • Market Cap: £5.05m
  • Beta: 0.00

Theracryf Overview

TheraCryf is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.

1 Day Chart (02-05-2025)

1 Day Chart

6 Month Chart

6 Month Chart

Financials

Latest F'cast
Div Yield 0.0% 0.0%
Div Cover n/a n/a
Op Mrgn -892.5% n/a
ROCE n/a  
Latest F'cast
P/E n/a n/a
PEG n/a n/a
Pr/Revenue 12.6 n/a
Pr/Book 2.2  
Latest F'cast
Revenue -9.1% n/a
PBT n/a n/a
EPS n/a n/a
DPS n/a n/a

Theracryf Fundamentals

Year Ending Revenue (£m) Pre-tax (£m) EPS P/E PEG EPS Grth. Div Yield
31-Mar-20 n/a (3.17) (2.07)p n/a n/a n/a n/a 0.0%
31-Mar-21 0.19 (3.21) (1.82)p n/a n/a n/a n/a 0.0%
31-Mar-22 n/a (3.17) (0.99)p n/a n/a n/a n/a 0.0%
31-Mar-23 0.44 (5.01) 1.47p 2.5 n/a n/a n/a 0.0%
31-Mar-24 0.40 (3.57) (1.14)p n/a n/a n/a n/a 0.0%

a. Based on UK GAAP presentation of accounts - includes discontinued activities

Theracryf Company Announcements

Board Appointment, Grant of Options, PDMR Dealing 01-May-2025 07:00 RNS
Holding(s) in Company 21-Mar-2025 15:55 RNS
Holding(s) in Company 20-Mar-2025 15:33 RNS

Latest Theracryf Director Deals

No deals were found in the last 28 days.

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: Above ratios are on a 'per annum' basis, adjusted for corporate actions and based on the fundamentals of the primary listed security.

Note 3: Under IFRS, all figures are based on 'Continuing' operations unless otherwise stated.

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing.

Note 5: Forecast figures based on normalised accounts.

 

Theracryf Market Data

Currency UK Pounds
Share Price 0.24p
Change Today 0.010p
% Change 4.44 %
52 Week High 1.22
52 Week Low 0.20
Volume 5,147,033
Shares Issued 2,148.96m
Market Cap £5.05m
Beta 0.00

Theracryf Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
45.2% below the market average45.2% below the market average45.2% below the market average45.2% below the market average45.2% below the market average
62.50% above the sector average62.50% above the sector average62.50% above the sector average62.50% above the sector average62.50% above the sector average
Price Trend
95.51% below the market average95.51% below the market average95.51% below the market average95.51% below the market average95.51% below the market average
83.33% below the sector average83.33% below the sector average83.33% below the sector average83.33% below the sector average83.33% below the sector average
Income Not Available
Growth
17.06% below the market average17.06% below the market average17.06% below the market average17.06% below the market average17.06% below the market average
31.25% below the sector average31.25% below the sector average31.25% below the sector average31.25% below the sector average31.25% below the sector average

Theracryf Dividends

No dividends found

Trades for 02-May-2025

Time Volume / Share Price
15:36 629 @ 0.27p
15:24 500,000 @ 0.25p
15:23 996,420 @ 0.25p
14:58 1,500,000 @ 0.25p
14:57 798,403 @ 0.25p

Theracryf Key Personnel

CEO Huw Jones
CFO Toni Hänninen

Top of Page